SCHEMBL30830801

SCHEMBL30830801

Cc1cc(O)ccc1-c1ccc(OCc2ccccc2)nc1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 1/20 0.48
▸ BAK1 Q16611 1/20 0.48
▸ ESR2 Q92731 3/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ MAPK10 P53779 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ GRM5 P41594 1/20 0.41
▸ LMNA P02545 3/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ PTGS1 P23219 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ PTGS2 P35354 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ HIF1A Q16665 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830608 0.91 MCL1 (0.47) MCL1BAK1ESR2L3MBTL1ALDH1A1
SCHEMBL19586153 0.86 L3MBTL1 (0.48) MCL1BAK1L3MBTL1ALDH1A1MAPT
SCHEMBL31134525 0.86 L3MBTL1 (0.43) MCL1BAK1L3MBTL1ALDH1A1MEN1
SCHEMBL30830765 0.83 PTGER1 (0.43) MCL1BAK1L3MBTL1MAPTGRM5
SCHEMBL25504166 0.81 MCL1 (0.43) MCL1BAK1ESR2L3MBTL1MAPT
SCHEMBL24207230 0.81 LMNA (0.47) L3MBTL1MAPTGRM5LMNACYP1A2
SCHEMBL31390651 0.81 LMNA (0.44) MCL1BAK1L3MBTL1ALDH1A1MEN1
SCHEMBL30475462 0.80 SQOR (0.44) MCL1BAK1L3MBTL1MAPTGRM5
SCHEMBL25035127 0.80 SQOR (0.44) MCL1BAK1L3MBTL1MAPTGRM5
SCHEMBL31444197 0.80 ESR2 (0.47) MCL1BAK1ESR2GRM5LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback